Result: Risk Minimisation Materials for medicines starting with the letter I

Ibandronic acid

Accord-UK Ltd

Ibandronic Acid - Patient Reminder Card

This reminder card contains important safety information that you need to be aware of before and during treatment with Ibandronic acid 3mg Solution for Injection for treatment of osteoporosis in postmenopausal women at increased risk of fracture

Idacio

Fresenius Kabi Ltd

Idacio Paediatric Patient Alert Card

This card contains important safety information for caregivers of paediatric patients being treated with Idacio .

Idacio Patient Alert Card

This contains important safety information for patients being treated with Idacio.

Ilaris

Novartis Pharmaceuticals UK Ltd

Ilaris - Important information for patients with Gouty Arthritis

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Gouty Arthritis

Ilaris - Important information for patients with Period Fever Syndromes

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Periodic Fever Syndromes CAPS, TRAPS, HIDS/MKD or FMF

Ilaris - Important information for the patient with Still's Disease (including Adult Onset Still's Disease) and Systemic Juvenile Idiopathic Arthritis

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Still's Disease (including Adult Onset Still's Disease) and Systemic Juvenile Idiopathic Arthritis

Iluvien

Alimera Sciences Limited

ILUVIEN® Administration Guide

Guidance on the administration technique and important adverse events

For Healthcare Professionals

ILUVIEN® Administration Video

This Physician training video provides visual and written instructions on the appropriate use of ILUVIEN including preparation, administration and aftercare.

For Healthcare Professionals

ILUVIEN® Patient Guide

A patient guide to ILUVIEN containing safety information.

Imlygic

Amgen Ltd

IMLYGIC Information for Patients and Close Contacts

This brochure contains important safety information you should know before and during IMLYGIC treatment. Please read this information carefully before and after each treatment. Please also read the IMLYGIC Package Leaflet. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

IMLYGIC Patient Alert Card

This IMLYGIC patient alert card includes contact details of the IMLYGIC prescriber, treatment start date, IMLYGIC batch number and information on the potential development of herpetic lesions and the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

IMLYGIC Physician's Brochure

This educational brochure contains important information regarding the risks of transmission and herpetic complications, and safe use and handling of IMLYGIC.This brochure does not contain a comprehensive description of the risks associated with IMLYGIC. Please read the current Summary of Product Characteristics (SmPC) for IMLYGIC. To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

Imnovid

Bristol-Myers Squibb Pharmaceuticals limited

Imnovid®▼ (pomalidomide) Adverse Event Form

The safe use of pomalidomide is of paramount importance. Adverse events (and cases of suspected or confirmed pregnancy or foetal exposure) should be reported to BMS. You can also report the event online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Healthcare Professional’s Information Pack

This pack contains the all the additional Risk Minimisation Materials required to prescribe and dispense pomalidomide. It also contains important reporting forms, information for patients, prescribing tools, and the Pharmacy Registration Form. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing pomalidomide for any patient.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Information for Healthcare Professionals

This brochure contains the information needed for prescribing and dispensing of pomalidomide, including information about the Pregnancy Prevention Programme. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing pomalidomide for any patient. Please also refer to the Summary of Product Characteristics (SmPC) for pomalidomide.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Information for Patients

This brochure should be given to patients receiving treatment with pomalidomide, as it provides important information about the pomalidomide Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking pomalidomide and how to report side effects.

Imnovid®▼ (pomalidomide) Male Treatment Initiation Form

This Treatment Initiation Form must be completed for each male patient prior to the initiation of their pomalidomide treatment. It is mandatory that male patients receive counselling and education to be made aware of the risks of pomalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of pomalidomide.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Patient Pocket Information Card

This card should be given to all patient as it reminds patients of the key educational information and risks of treatment with pomalidomide.

Imnovid®▼ (pomalidomide) Pharmacy Registration Form

This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense pomalidomide. In order to ensure that the actions to minimise the risk of foetal exposure are carried out for all patients, dispensing of pomalidomide will only be allowed from pharmacies registered with BMS.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Pregnancy Outcome Form

The safe use of pomalidomide is of paramount importance. Any cases of suspected or confirmed pregnancy or foetal exposure should be immediately reported to BMS. You can also report the event via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Use this form to provide information about the outcome of pregnancy.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Pregnancy Reporting Form

The safe use of pomalidomide is of paramount importance. Any cases of suspected or confirmed pregnancy or foetal exposure should be immediately reported to BMS. You can also report the event via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Prescription Authorisation Form

A newly completed Prescription Authorisation Form must accompany each pomalidomide prescription to confirm that the patient has been counselled about the teratogenic risk of pomalidomide and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Treatment Checklists and Algorithm

This checklist is to assist you with counselling a patient before they commence pomalidomide treatment in order to ensure it is used safely and correctly. The Algorithm provides high level steps for prescribing and dispensing of pomalidomide.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Woman of Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of childbearing potential prior to the initiation of their pomalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of pomalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of pomalidomide.

For Healthcare Professionals

Imnovid®▼ (pomalidomide) Woman of Non-Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of non-childbearing potential prior to the initiation of their pomalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of pomalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of pomalidomide.

For Healthcare Professionals

Imraldi

Biogen Biosimilars

Imraldi Patient Reminder Card

This card contains select important safety information that patients need to know before and during treatment with Imraldi.

Increlex

Ipsen Ltd

Increlex Dosing Guide

How to use Increlex in the treatment of severe primary IGF-1 deficiency

For Healthcare Professionals

Increlex Hypoglycaemia Leaflet

Information for parents, caregivers, or for patients about hypoglycaemia and what to do if it occurs

Increlex Instructions for Use

This leaflet is a quick reference guide to preparing and injecting Increlex®

Increlex Patient Leaflet

Patient educational information about severe primary IGF-1 deficiency and how Increlex® can help

Increlex Physician Leaflet

Physician information about Increlex® This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks, and it is advised therefore that it be read carefully before prescribing/dispensing/administering the product.

For Healthcare Professionals

Inflectra

Pfizer Limited

Inflectra Patient Reminder Card

The Reminder Card contains important safety information that you need to be aware of before and during treatment with Inflectra.

Instanyl

Takeda UK Ltd

Instanyl (fentanyl citrate) Single Dose Nasal Spray Patient's Guide

To be provided to patients receiving treatment with Instanyl by a HCP

Instanyl (fentanyl citrate) Single Dose Nasal Spray Pharmacist's Guide For Dispensing

Information leaflet for Pharmacists Administering Instanyl. It contains the dispensing checklist which is the required actions before Instanyl is supplied and useful contact information.

For Healthcare Professionals

Instanyl (fentanyl citrate) Single Dose Nasal Spray Physician's Guide For Prescribing

Information leaflet for Physicians Administering Instanyl. Contains Instanyl prescribing checklist information and required actions before Instanyl is supplied. Also it contains useful contact information.

For Healthcare Professionals

Intuniv

Takeda UK Ltd

Intuniv Chart 1: chart for the ongoing monitoring of patients during guanfacine treatment - HCP - Nov2017

Intuniv Chart 1: chart for the ongoing monitoring of patients during guanfacine treatment - HCP - Nov2017

For Healthcare Professionals

Intuniv Checklist 1: checklist for use prior to initiating treatment with guanfacine - HCP - Nov2017

Intuniv Checklist 1: checklist for use prior to initiating treatment with guanfacine - HCP - Nov2017

For Healthcare Professionals

Intuniv Checklist 2: checklist for the ongoing monitoring & management of patients during guanfacine treatment - HCP - Nov2017

Intuniv Checklist 2: checklist for the ongoing monitoring & management of patients during guanfacine treatment - HCP -Nov2017

For Healthcare Professionals

Intuniv Checklist 3: checklist for discontinuation of guanfacine & during downward titration - HCP - Nov2017

Intuniv Checklist 3: checklist for discontinuation of guanfacine & during downward titration - HCP - Nov2017

For Healthcare Professionals

Intuniv HCP Guide - Nov2017

Intuniv HCP Guide - Nov2017

For Healthcare Professionals

Irbesartan+Hydrochlorothiazide

Aurobindo Pharma - Milpharm Ltd.

Irbesartan/HCTZ- HCP letter- Hydrochlorothiazide and the risk of non-melanoma skin cancer

The prescriber should inform the patients taking hydrochlorothiazide (HCTZ) containing medicines of the risk of non-melanoma skin cancer. Patients should be advised to limit the exposure to sunlight and UV rays and use adequate protection when exposed to sunlight and UV rays to minimise the risk of skin cancer

For Healthcare Professionals

Isotretinoin

Mylan

Isotretinoin Patient Reminder Card

This material is provided by Mylan as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme.

Isotretinoin Pharmacist Checklist

This material is provided by Mylan as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme.

For Healthcare Professionals

Isotretinoin Prescriber Checklist

This material is provided by Mylan as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme.

For Healthcare Professionals

Ennogen Healthcare Ltd

Isotretinoin Soft Capsules Patient Alert Card

Patient Reminder Card for Isotretinoin - Important information to know when taking isotretinoin and what you must do.

Isotretinoin Soft Capsules Pharmacist Checklist

Guidance for dispensing Oral Isotretinoin. Isotretinoin is strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions in the Isotretinoin Pregnancy Prevention Programme are fulfilled.

For Healthcare Professionals

Isotretinoin Soft Capsules Prescribers Checklist

Acknowledgement Form for Prescribing Isotretinoin to Female Patients. The potential for pregnancy must be assessed for all female patients prescribed Isotretinoin.

For Healthcare Professionals

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Patient Reminder Card

Patient Reminder Card for Isotretinoin - Important information to know when taking isotretinoin and what you must do.

Pharmacist checklist

Guidance for dispensing Oral Isotretinoin. Isotretinoin is strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions in the Isotretinoin Pregnancy Prevention Programme are fulfilled

For Healthcare Professionals

Prescriber checklist

Acknowledgement Form for Prescribing Isotretinoin to Female Patients. The potential for pregnancy must be assessed for all female patients prescribed Isotretinoin.

For Healthcare Professionals